Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. (ATTBF) Revenue
Annual & quarterly revenue history · segment & region breakdown
ATTBF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAbattis Bioceuticals Corp. trailing twelve-month (TTM) revenue is $0.00B, an increase of 4163.24% year-over-year from $0.00B in FY2019.
Revenue trend
2019 – 2008 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2019-09-30 | $0.00B | +$0.00B | +4163.24% |
| 2018-09-30 | $0.00B | +$0.00B | — |
| 2017-09-30 | $0.00B | +$0.00B | — |
| 2016-09-30 | $0.00B | -$0.00B | -100.00% |
| 2015-09-30 | $0.00B | +$0.00B | +1090.93% |
| 2014-09-30 | $0.00B | -$0.00B | -55.75% |
| 2013-09-30 | $0.00B | +$0.00B | — |
| 2012-09-30 | $0.00B | +$0.00B | — |
| 2011-09-30 | $0.00B | +$0.00B | — |
| 2010-09-30 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Abattis Bioceuticals Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Abattis Bioceuticals Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Abattis Bioceuticals Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ATTBF revenue · 4 questionsATTBF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 4163.24% year-over-year from $0.00B in FY2019.
▸ Source: FMP · Abattis Bioceuticals Corp. SEC filings · GAAP · Abattis Bioceuticals Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026